Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Clinical Trial ID NCT01024231

PubWeight™ 61.46‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01024231

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013 17.53
2 Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011 6.44
3 Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013 3.48
4 Deciphering and reversing tumor immune suppression. Immunity 2013 2.24
5 Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013 2.03
6 PD-1 as a potential target in cancer therapy. Cancer Med 2013 1.98
7 At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013 1.90
8 Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Invest 2015 1.67
9 Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med 2014 1.59
10 The role of B7 family molecules in hematologic malignancy. Blood 2012 1.47
11 Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 2013 1.39
12 Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014 1.32
13 Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol 2013 1.29
14 Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014 1.22
15 Pathways and therapeutic targets in melanoma. Oncotarget 2014 1.17
16 Prostate cancer immunotherapy. Clin Cancer Res 2011 1.11
17 Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol 2013 1.04
18 Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J 2012 0.97
19 Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. Ann Oncol 2013 0.96
20 Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr Oncol Rep 2013 0.94
21 The efficacy of anti-PD-1 agents in acral and mucosal melanoma. Cancer 2016 0.92
22 New combinations and immunotherapies for melanoma: latest evidence and clinical utility. Ther Adv Med Oncol 2013 0.92
23 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
24 Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm. Mol Cancer Ther 2012 0.91
25 Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res 2014 0.87
26 Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med 2012 0.87
27 Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Oncoimmunology 2012 0.87
28 Metastatic melanoma - a review of current and future drugs. Drugs Context 2012 0.83
29 Targeting CD8+ T-cell tolerance for cancer immunotherapy. Immunotherapy 2014 0.81
30 PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother 2014 0.80
31 Biomarkers as key contributors in treating malignant melanoma metastases. Dermatol Res Pract 2011 0.79
32 Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more. Oncoimmunology 2012 0.78
33 Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015. J Transl Med 2016 0.77
34 Immunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol 2012 0.77
35 The role of checkpoints in the treatment of GBM. J Neurooncol 2015 0.75
36 Adding fuel to the fire: immunogenic intensification. Hum Vaccin Immunother 2014 0.75
37 Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal Perforation. Cornea 2016 0.75
Next 100